

Global Multiple Myeloma Therapeutics Market Size study, by Drug, Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), End Use, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G404E6200F59EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G404E6200F59EN

Abstracts

The Global Multiple Myeloma Therapeutics Market is valued at approximately USD 20.87 billion in 2023 and is anticipated to grow at a steady compound annual growth rate of more than 5.5% over the forecast period 2024 to 2032. Multiple myeloma, a complex and often incurable hematological malignancy of plasma cells, remains a formidable clinical challenge despite the progress of recent decades. However, continuous therapeutic advancements, especially in immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, and cell-based therapies, are transforming the treatment landscape with higher survival outcomes and prolonged remission periods. Increasing emphasis on early detection and risk-adapted therapy has positioned novel therapeutics at the heart of modern oncological strategies for managing both active and smoldering disease forms.

Market expansion is being shaped by a dynamic mix of scientific innovation, robust clinical trial activity, and expanded indications for next-generation drugs. Carfilzomib, daratumumab, and lenalidomide are among the most prominent agents being integrated into front-line treatment regimens, bolstered by encouraging long-term data and real-world evidence. Furthermore, the integration of personalized treatment protocols—particularly those guided by cytogenetic and molecular profiling—continues to optimize outcomes and patient selection. The paradigm is rapidly shifting toward combination regimens and maintenance therapies that aim to extend progression-free survival while reducing resistance development. Additionally, regulatory bodies have facilitated faster drug approvals via breakthrough and orphan designations, helping to accelerate the market's momentum.

Nevertheless, the market still contends with notable limitations. High treatment costs, particularly for targeted and cellular therapies, remain a pressing concern for healthcare systems and patients alike. Access to novel therapies can be inconsistent, especially in developing regions, where limited reimbursement infrastructure hampers widespread adoption. Moreover, treatment-related toxicities, therapy resistance, and disease relapse continue to impede complete eradication. Despite these challenges, the future outlook remains optimistic, underpinned by pipeline innovations including bispecific T-cell engagers (BiTEs), CAR T-cell therapies, and the increasing involvement of artificial intelligence in trial design and predictive diagnostics.

From a geographical standpoint, North America dominates the global multiple myeloma therapeutics market, driven by strong R&D funding, high disease awareness, and swift adoption of innovative treatments. The U.S., in particular, commands a significant share due to its comprehensive insurance coverage and presence of major pharmaceutical leaders. Europe trails closely behind, supported by favorable regulatory landscapes and expanded access programs in countries like Germany, France, and the UK. Meanwhile, the Asia Pacific region is forecasted to witness the highest growth rate over the next decade. Increasing geriatric population, improving healthcare infrastructure, and escalating government investments in oncology care are expected to catalyze growth in countries such as China, India, and Japan. Latin America and the Middle East & Africa also show emerging promise, fueled by cross-border collaborations and gradual integration of advanced therapeutics into clinical practice.

Major market player included in this report are:

Bristol-Myers Squibb Company

Johnson & Johnson

Amgen Inc.

AbbVie Inc.

Sanofi S.A.

Novartis AG

Pfizer Inc.

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Takeda Pharmaceutical Company Limited

Merck & Co., Inc.

Oncopeptides AB

Karyopharm Therapeutics Inc.

Teva Pharmaceutical Industries Ltd.

BeiGene Ltd.

The detailed segments and sub-segment of the market are explained below:

By Drug

Immunomodulators

Proteasome Inhibitors

Monoclonal Antibodies

Others

By Disease

Active Multiple Myeloma

Smoldering Multiple Myeloma

By End Use

Hospitals

Specialty Clinics

Cancer & Hematology Centers

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET EXECUTIVE SUMMARY

- 1.1. Global Multiple Myeloma Therapeutics Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug
 - 1.3.2. By Disease
 - 1.3.3. By End Use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspectives)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Rising Incidence & Early Detection
 - 2.3.4.2. Personalized Therapy Protocols
 - 2.3.4.3. Expanded Clinical Trial Activity
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
 - Historical year – 2022
 - Base year – 2023
 - Forecast period – 2024 to 2032
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Continuous Therapeutic Advancements & Novel Agents
- 3.1.2. Personalized, Risk-Adapted Treatment Protocols
- 3.1.3. Regulatory Fast-Track & Orphan Drug Designations

3.2. Market Challenges

- 3.2.1. High Cost & Access Disparities in Emerging Regions
- 3.2.2. Treatment Resistance, Toxicities & Disease Relapse

3.3. Market Opportunities

- 3.3.1. Pipeline Innovations: BiTEs & CAR-T Therapies
- 3.3.2. AI-Driven Trial Design & Predictive Diagnostics
- 3.3.3. Combination Regimens & Maintenance Strategies

CHAPTER 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE & FORECASTS BY DRUG 2022–2032

5.1. Segment Dashboard

5.2. Immunomodulators, Proteasome Inhibitors, Monoclonal Antibodies & Others Revenue Trend Analysis, 2022 & 2032 (USD Billion)

CHAPTER 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE & FORECASTS BY DISEASE 2022–2032

6.1. Segment Dashboard

6.2. Active Multiple Myeloma vs. Smoldering Multiple Myeloma Revenue Trend Analysis, 2022 & 2032 (USD Billion)

CHAPTER 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE & FORECASTS BY END USE 2022–2032

7.1. Segment Dashboard

7.2. Hospitals, Specialty Clinics, Cancer & Hematology Centers & Others Revenue Trend Analysis, 2022 & 2032 (USD Billion)

CHAPTER 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022–2032

8.1. North America Market

8.1.1. U.S.

8.1.2. Canada

8.2. Europe Market

8.2.1. UK

8.2.2. Germany

8.2.3. France

8.2.4. Spain

8.2.5. Italy

8.2.6. Rest of Europe

8.3. Asia Pacific Market

8.3.1. China

8.3.2. India

8.3.3. Japan

- 8.3.4. Australia
- 8.3.5. South Korea
- 8.3.6. Rest of Asia Pacific
- 8.4. Latin America Market
 - 8.4.1. Brazil
 - 8.4.2. Mexico
 - 8.4.3. Rest of Latin America
- 8.5. Middle East & Africa Market
 - 8.5.1. Saudi Arabia
 - 8.5.2. South Africa
 - 8.5.3. Rest of Middle East & Africa

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Bristol-Myers Squibb Company
 - 9.1.2. Johnson & Johnson
 - 9.1.3. Amgen Inc.
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Bristol-Myers Squibb Company
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
 - 9.3.2. Johnson & Johnson
 - 9.3.3. Amgen Inc.
 - 9.3.4. AbbVie Inc.
 - 9.3.5. Sanofi S.A.
 - 9.3.6. Novartis AG
 - 9.3.7. Pfizer Inc.
 - 9.3.8. F. Hoffmann-La Roche Ltd
 - 9.3.9. GlaxoSmithKline plc
 - 9.3.10. Takeda Pharmaceutical Company Limited
 - 9.3.11. Merck & Co., Inc.
 - 9.3.12. Oncopeptides AB
 - 9.3.13. Karyopharm Therapeutics Inc.
 - 9.3.14. Teva Pharmaceutical Industries Ltd.

9.3.15. BeiGene Ltd.

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

10.2. Research Attributes

I would like to order

Product name: Global Multiple Myeloma Therapeutics Market Size study, by Drug, Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), End Use, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G404E6200F59EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G404E6200F59EN.html>